Monoclonal Antibodies Market Size, Share & Trends Report

Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2018 - 2024

  • Published Date: Nov, 2016
  • Base Year for Estimate: 2015
  • Report ID: GVR-1-68038-280-8
  • Format: Electronic (PDF)
  • Historical Data: 2013 - 2015
  • Number of Pages: 115

Table of Contents

Chapter 1 Research Methodology & Scope
                    1.1 Region Wise Market Calculation
                       1.1.1 Region Wise Market: Base Estimates
                       1.1.2 Global Market: CAGR Calculation
                    1.2 Region based segment share calculation
                    1.3 List of Secondary Sources
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
                    4.1 Market segmentation & scope
                       4.1.1 Market Driver Analysis
                             4.1.1.1 Increasing incidences of chronic diseases
                             4.1.1.2 Technological advancements
                             4.1.1.3 Growing awareness levels
                    4.2 Market Restraint Analysis
                             4.2.1.1 High cost of therapeutic mAbs
                    4.3 Penetration & growth prospect mapping
                    4.4 Monoclonal Antibodies - SWOT Analysis, By Factor (political & legal, economic and technological)
                    4.5 Industry Analysis - Porter’s
Chapter 5 Market Categorization 1: Source Type Estimates & Trend Analysis
                    5.1 Monoclonal antibodies market: Source type movement analysis
                    5.2 Murine
                       5.2.1 Murine market, 2013 - 2024 (USD Billion)
                    5.3 Chimeric
                       5.3.1 Chimeric market, 2013 - 2024 (USD Billion)
                    5.4 Humanized
                       5.4.1 Humanized market, 2013 - 2024 (USD Billion)
                    5.5 Human
                             5.5.1.1 Human market, 2013 - 2024 (USD Billion)
Chapter 6 Market Categorization 2: Production Type Estimates & Trend Analysis
                    6.1 Monoclonal antibodies market: Production type movement analysis
                    6.2 In vitro
                       6.2.1 In vitro market, 2013 - 2024 (USD Billion)
                    6.3 In vivo
                       6.3.1 In vivo market, 2013 - 2024 (USD Billion)
Chapter 7 Market Categorization 3: Indication Estimates & Trend Analysis
                    7.1 Monoclonal antibodies market: Disease movement analysis
                    7.2 Cancer
                       7.2.1 Cancer Market, 2013 - 2024 (USD Billion)
                    7.3 Autoimmune diseases
                       7.3.1 Autoimmune diseases market, 2013 - 2024 (USD Billion)
                    7.4 Inflammatory diseases
                       7.4.1 Inflammatory diseases market, 2013 - 2024 (USD Billion)
                    7.5 Infectious diseases
                       7.5.1 Infectious diseases market, 2013 - 2024 (USD Billion)
                    7.6 Microbial diseases
                       7.6.1 Microbial diseases market, 2013 - 2024 (USD Billion)
                    7.7 Others
                       7.7.1 Others diseases market, 2013 - 2024 (USD Billion)
Chapter 8 Market Categorization 4: End-Use Estimates & Trend Analysis
                    8.1 Monoclonal antibodies market: End-use movement analysis
                    8.2 Hospitals
                       8.2.1 Hospitals market, 2013 - 2024 (USD Billion)
                    8.3 Research Institutes
                       8.3.1 Research institutes market, 2013 - 2024 (USD Billion)
                    8.4 Others
                       8.4.1 Others market, 2013 - 2024 (USD Billion)
Chapter 9 Market Categorization 5: Regional Estimates & Trend Analysis, by Source Type, Production Type, Indication & End-Use
                    9.1 Monoclonal antibodies market shares by region, 2015 & 2024
                    9.2 North America
                       9.2.1 North America Monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.2.2 The U.S.
                             9.2.2.1 The U.S. monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.2.3 Canada
                             9.2.3.1 Canada monoclonal antibodies market estimates and forecasts, 2013 - 2024
                    9.3 Europe
                             9.3.1.1 Europe monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.3.2 Germany
                             9.3.2.1 Germany monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.3.3 The U.K.
                             9.3.3.1 The U.K. monoclonal antibodies market estimates and forecasts, 2013 - 2024
                    9.4 Asia Pacific
                             9.4.1.1 Asia Pacific monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.4.2 Japan
                             9.4.2.1 Japan monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.4.3 China
                             9.4.3.1 China monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.4.4 India
                             9.4.4.1 India monoclonal antibodies market estimates and forecasts, 2013 - 2024
                    9.5 Latin America
                             9.5.1.1 Latin America monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.5.2 Brazil
                             9.5.2.1 Brazil monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.5.3 Mexico
                             9.5.3.1 Mexico monoclonal antibodies market estimates and forecasts, 2013 - 2024
                    9.6 MEA
                             9.6.1.1 MEA monoclonal antibodies market estimates and forecasts, 2013 - 2024
                       9.6.2 South Africa
                             9.6.2.1 South Africa Monoclonal antibodies market estimates and forecasts, 2013 - 2024
Chapter 10 Competitive Landscape
                    10.1 Strategy framework
                    10.2 Market participation categorization
                    10.3 Company Profiles
                       10.3.1 Novartis International
                             10.3.1.1 Company Overview
                             10.3.1.2 Financial Performance
                             10.3.1.3 Product Benchmarking
                             10.3.1.4 Strategic Initiatives
                       10.3.2 Pfizer
                             10.3.2.1 Company Overview
                             10.3.2.2 Financial Performance
                             10.3.2.3 Product Benchmarking
                             10.3.2.4 Strategic Initiatives
                       10.3.3 GlaxoSmithKline Plc
                             10.3.3.1 Company Overview
                             10.3.3.2 Financial Performance
                             10.3.3.3 Product Benchmarking
                             10.3.3.4 Strategic Initiatives
                       10.3.4 Amgen Inc.
                             10.3.4.1 Company Overview
                             10.3.4.2 Financial Performance
                             10.3.4.3 Product Benchmarking
                             10.3.4.4 Strategic Initiatives
                       10.3.5 Merck & Co., Inc.
                             10.3.5.1 Company Overview
                             10.3.5.2 Financial Performance
                             10.3.5.3 Product Benchmarking
                             10.3.5.4 Strategic Initiatives
                       10.3.6 Daiichi Sankyo
                             10.3.6.1 Company Overview
                             10.3.6.2 Financial Performance
                             10.3.6.3 Product Benchmarking
                             10.3.6.4 Strategic Initiatives
                       10.3.7 Abbott Laboratories
                             10.3.7.1 Company Overview
                             10.3.7.2 Financial Performance
                             10.3.7.3 Product Benchmarking
                             10.3.7.4 Strategic Initiatives
                       10.3.8 AstraZeneca plc
                             10.3.8.1 Company Overview
                             10.3.8.2 Financial Performance
                             10.3.8.3 Product Benchmarking
                             10.3.8.4 Strategic Initiatives
                       10.3.9 Eli Lilly
                             10.3.9.1 Company Overview
                             10.3.9.2 Financial Performance
                             10.3.9.3 Product Benchmarking
                             10.3.9.4 Strategic Initiatives
                       10.3.10 Johnson & Johnson
                             10.3.10.1 Company Overview
                             10.3.10.2 Financial Performance
                             10.3.10.3 Product Benchmarking
                             10.3.10.4 Strategic Initiatives
                       10.3.11 Bayer AG
                             10.3.11.1 Company Overview
                             10.3.11.2 Financial Performance
                             10.3.11.3 Product Benchmarking
                             10.3.11.4 Strategic Initiatives
                       10.3.12 Bristol Myers Squibb
                             10.3.12.1 Company Overview
                             10.3.12.2 Financial Performance
                             10.3.12.3 Product Benchmarking
                             10.3.12.4 Strategic Initiatives
                       10.3.13 F.Hoffman-La Roche Ltd.
                             10.3.13.1 Company Overview
                             10.3.13.2 Financial Performance
                             10.3.13.3 Product Benchmarking
                             10.3.13.4 Strategic Initiatives
                       10.3.14 Mylan N.V.
                             10.3.14.1 Company Overview
                             10.3.14.2 Financial Performance
                             10.3.14.3 Product Benchmarking
                             10.3.14.4 Strategic Initiatives
                       10.3.15 Biogen Idec Inc.
                             10.3.15.1 Company Overview
                             10.3.15.2 Financial Performance
                             10.3.15.3 Product Benchmarking
                             10.3.15.4 Strategic Initiatives
                       10.3.16 Thermo Fisher Scientific
                             10.3.16.1 Company Overview
                             10.3.16.2 Financial Performance
                             10.3.16.3 Product Benchmarking
                             10.3.16.4 Strategic Initiatives
                       10.3.17 Novo Nordisk
                             10.3.17.1 Company Overview
                             10.3.17.2 Financial Performance
                             10.3.17.3 Product Benchmarking
                             10.3.17.4 Strategic Initiatives
                       10.3.18 Sanofi
                             10.3.18.1 Company Overview
                             10.3.18.2 Financial Performance
                             10.3.18.3 Product Benchmarking
                             10.3.18.4 Strategic Initiatives
                       10.3.19 Genzyme
                             10.3.19.1 Company Overview
                             10.3.19.2 Financial Performance
                             10.3.19.3 Product Benchmarking
                             10.3.19.4 Strategic Initiatives


List of Tables

TABLE 1 Country share estimation
TABLE 2 North America monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 3 North America monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 4 North America monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 5 North America monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 6 The U.S. monoclonal antibodies market, by source type, 2013 - 2024 (USD billion)
TABLE 7 The U.S. monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 8 The U.S. monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 9 The U.S. monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 10 Canada monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 11 Canada monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 12 Canada monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 13 Canada monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 14 Europe monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 15 Europe monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 16 Europe monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 17 Europe monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 18 Europe monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 19 Germany monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 20 Germany monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 21 Germany monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 22 Germany monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 23 The U.K. monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 24 The U.K. monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 25 The U.K. monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 26 The U.K. monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 27 Asia Pacific monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 28 Asia Pacific monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 29 Asia Pacific monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 30 Asia Pacific monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 31 Japan monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 32 Japan monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 33 Japan monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 34 Japan monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 35 China monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 36 China monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 37 China monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 38 China monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 39 India monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 40 India monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 41 Latin America monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 42 Latin America monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 43 Latin America monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 44 Latin America monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 45 Brazil monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 46 Brazil monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 47 Brazil monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 48 Brazil monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 49 Mexico monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 50 Mexico monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 51 Mexico monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 52 Mexico Monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 53 MEA monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 54 MEA monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 55 MEA monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 56 MEA monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)
TABLE 57 South Africa monoclonal antibodies market, by source type, 2013 - 2024 (USD Billion)
TABLE 58 South Africa monoclonal antibodies market, by production type, 2013 - 2024 (USD Billion)
TABLE 59 South Africa monoclonal antibodies market, by indication, 2013 - 2024 (USD Billion)
TABLE 60 South Africa monoclonal antibodies market, by end-use, 2013 - 2024 (USD Billion)


List of Figures

FIG. 1 Market summary (USD Billion)
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Monoclonal antibodies market technology outlook key takeaways
FIG. 10 Monoclonal antibodies market: Source type movement analysis
FIG. 11 Global murine market, 2013 - 2024 (USD Billion)
FIG. 12 Global chimeric market, 2013 - 2024 (USD Billion)
FIG. 13 Global humanized market, 2013 - 2024 (USD Billion)
FIG. 14 Global human market, 2013 - 2024 (USD Billion)
FIG. 15 Monoclonal antibodies market production type outlook: Key takeaways
FIG. 16 Monoclonal antibodies market: Production type movement analysis
FIG. 17 Global in-vitro market, 2013 - 2024 (USD Billion)
FIG. 18 Global in vivo market, 2013 - 2024 (USD Billion)
FIG. 19 Monoclonal antibodies market disease outlook: Key takeaways
FIG. 20 Monoclonal antibodies market: Disease movement analysis
FIG. 21 Global cancer market, 2013 - 2024 (USD Billion)
FIG. 22 Global autoimmune diseases market, 2013 - 2024 (USD Billion)
FIG. 23 Global inflammatory diseases market, 2013 - 2024 (USD Billion)
FIG. 24 Global infectious diseases market, 2013 - 2024 (USD Billion)
FIG. 25 Global microbial diseases market, 2013 - 2024 (USD Billion)
FIG. 26 Global others market, 2013 - 2024 (USD Billion)
FIG. 27 Monoclonal antibodies market end-use outlook: Key takeaways
FIG. 28 Monoclonal antibodies market: End-use movement analysis
FIG. 29 Global hospitals market, 2013 - 2024 (USD Billion)
FIG. 30 Global research institutes market, 2013 - 2024 (USD Billion)
FIG. 31 Global others market, 2013 - 2024 (USD Billion)
FIG. 32 Regional market place: Key takeaways
FIG. 33 Regional outlook, 2015 & 2024
FIG. 34 North America monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 35 The U.S. monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 36 Canada monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 37 Europe monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 38 Germany monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 39 The U.K. monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 40 Asia Pacific monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 41 Japan monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 42 China monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 43 India monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 44 Latin America monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 45 Brazil monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 46 Mexico monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 47 MEA monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 48 South Africa Monoclonal antibodies market, 2013 - 2024 (USD Billion)
FIG. 49 Strategy framework
FIG. 50 Participant categorization

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.